Pfizer, Novartis ink respiratory deal

Share this article:

Pfizer has inked a deal to market Novartis's chronic obstructive pulmonary disease drug Seebri Breezhaler (glycopyrronium bromide) and the Ultimo Breezhaler (indacaterol/glycopyrronium bromide) in Great Britain. Pfizer said in a statement that the country's National Health Service estimates around three million residents have COPD, one of the most common respiratory diseases.

The category has gotten a significant amount of attention of late, such as GlaxoSmithKline's efforts to shore up its Ellipta franchise and AstraZeneca's recent Almirall purchase to beef up its respiratory portfolio.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION